

# Federal Efforts to Prevent Drug Shortages

## **An FDA Perspective**

Douglas C. Throckmorton, MD
Deputy Director for Regulatory Programs
Center for Drug Evaluation and Research
FDA

Duke Margolis Center for Health Policy

November 27, 2018

### **Definitions of Medical Product Shortage**




- **Drug Shortage (FDA):** A *drug shortage* means a period when the demand or projected demand for the drug within the United States exceeds the supply of the drug.
- **Drug Shortage (ASHP\*):** A drug product is in shortage:
  - once the shortage is verified with manufacturers
  - when supply issues affect how a pharmacy prepares or dispenses a drug product, or influence patient care requiring prescribers to use an alternative therapy

\*ASHP: American Society of Health-System Pharmacists

#### **Trends in New Drug Shortages 2010-2017**





From FDA Drug Shortage Report to Congress, 2017 https://www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/U CM610662.pdf




# Sources of Shortages: Manufacturing Challenges

- Consolidation in manufacturing of sterile injectables
  - In Fall of 2017, interruption of manufacturing by a single firm led to shortages of multiple critical drugs including injectable narcotics, "caines" and others drugs
- Shortages of critical sterile injectable drugs from increased demand or manufacturing problems
  - IV electrolyte salts, Magnesium Sulfate, Calcium Gluconate and Potassium Chloride

#### **Sources of Shortages: Natural Disasters**





- Hurricane Maria affected multiple manufacturers in Puerto Rico
  - IV fluid shortages which began in 2014 were worsened due to Baxter facility impact in PR

#### What FDA <u>Does</u> to Address Drug Shortages









- Drug Shortage Staff focused on addressing drug shortages
  - Facilitate temporary and long-term strategies to address shortages
  - Coordinate timely and comprehensive risk/benefit decisions within FDA
    - Personnel across multiple FDA Offices involved in shortage response
  - Distribute information (web posting, professional organizations):
    - https://www.fda.gov/Drugs/DrugSafety/DrugShortages/default.htm
- Goal: Maintain availability while minimizing risk to patients





- FDA cannot require:
  - A company to disclose details of why a shortage occurs
  - A company to make a drug
  - A company to make more of a drug
  - How much and to whom the drug is distributed

#### **Lessons Learned**



- Availability of drugs for patients is critical for healthcare
  - Interruptions of drug manufacturing due to any reason can lead to drug shortages with devastating impact on public health
- Sources of drug shortages include manufacturing challenges and natural disasters
  - FDA response tailored to address underlying cause(s)
  - Communications and information sharing are critical both to preventing and to mitigating shortages
- Recovery from shortages takes time. <u>Prevention</u> is critical to reducing the numbers of drug shortages

#### **Communication is Critical**



- Requirements to Industry For Early Notification
- Manufacturers are required to notify the FDA of a permanent discontinuance or interruption in manufacturing that is likely to lead to a meaningful disruption in the supply of a covered drug in the United States
  - At least 6 months in advance of but in no case later than 5 business days after the interruption in manufacturing occurs
  - Not limited to medically necessary products
  - Regardless of market share, or number of companies marketing, or wholesaler volumes



#### **Today's Meeting**



- Discussion goals:
  - Root Causes of drug shortages
    - Economics of drug shortages
      - Measurement of shortages and their public health impact
      - Economic drivers underlying drug shortages
    - Manufacturing and Distribution
      - Anticipating vulnerabilities, eliminating barriers to adequate drug supply
  - Potential tools to address drug shortages
    - Market-driven actions
    - Governmental actions
      - Incentives to encourage adequate drug supply and manufacturing redundancy and resiliency



## **Thank You**

